secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theseus Pharmaceuticals, Inc. (—)
CIK:        0001745020
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001104659-24-023155
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theseus acquired by Concentra for $4.05/share + CVR; delisting from Nasdaq
--------------------------------------------------------------------------

- Tender offer closed Feb 13 with 83.3% (37,211,244 shares) tendered; merger completed Feb 14.
- Stockholders received $4.05 cash per share plus one CVR representing potential future payments.
- Board of directors resigned; new directors and officers include Kevin Tang (CEO) and Michael Hearne (CFO).
- Company requested delisting from Nasdaq and intends to deregister under Section 12(g) of Exchange Act.
- Controlled equity offering agreement with Cantor Fitzgerald terminated effective as of closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/0001104659-24-023155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745020/000110465924023155/tm246030d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-023155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer